Cipla Ltd — Q3 FY24
Cipla delivered a strong Q3 FY24 with revenue of INR 6,544 crore (+14% YoY) and EBITDA margin of 26.3%, driven by market-leading growth in India (+12%), an all-time high US reve...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY24
Generic Symbicort filing in Q3 FY24
Cipla plans to file generic Symbicort in Q3 FY24, having completed clinical studies.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY24
Peptide product launch in Q4 FY24
One peptide product launch planned in Q4 FY24, with 3-4 more in FY25.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY24
US revenue sustainable range of $220-225M next quarter
Management guided US revenue of $220-225M as sustainable for the next quarter.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1